LONGEVERON INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Geoff Green, Chief Execuive Officer of Longeveron Inc. (the "Company") is presenting at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participating in a panel discussion entitled "The Emerging Cell & Gene Therapy Landscape-From Hope to Reality."

The pre-recorded company presentation will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022, and a link to the presentation will be available at the same time via the Investors & Media section of the Company website (www.longeveron.com). The panel discussion will be available to registered conference attendees. .

A copy of the presentation materials is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information presented in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

 (d) Exhibits




Exhibit No.                                    Description
99.1            Presentation for H.C. Wainwright & Co. BioConnect 2022 Virtual Conference
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses